LONDON — A mutated influenza strain is spreading early in Europe this winter, but some experts warn talk of a “superflu” is misleading, erodes public trust and distracts from the underlying problems of the National Health Service. The new strain has triggered dramatic headlines in the U.K., where health leaders are warning of a “worst-case scenario” for the country’s NHS. Health Secretary Wes Streeting described it as a “tidal wave of flu tearing through our hospitals” and labelled it a “challenge unlike any [the NHS] has seen since the pandemic.” While hospital admissions have been rising sharply due to the early arrival of flu season, there is currently no evidence that this season’s variant is more deadly or transmissible, experts at the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) told POLITICO. Neither does the data suggest hospital admissions will peak higher than previous years — although this is possible — just that they’re a few weeks early. But some experts in the U.K. have criticized the government’s “superflu” narrative, suggesting it’s being used as leverage in talks on doctor pay and conditions ahead of a looming strike. Prime Minister Keir Starmer wrote in The Guardian Friday it was “beyond belief” doctors would consider striking in these “potentially dire” circumstances, citing “a superflu epidemic.” The British Medical Association (BMA), the union representing resident doctors due to go on strike Wednesday, claimed it was “irresponsible to portray the current winter flu crisis as unprecedented” given that rates of infection and hospitalization were “comparable to most years,” a spokesperson told POLITICO. Mathematician Christina Pagel, a professor at University College London, said the “superflu” line was based on the “highly misleading use of statistics” and had more to do with the impending doctors’ strike than real trends. When contacted by POLITICO, the U.K. government stood by its health leaders’ warnings of the current flu season, in which they described it as an “unprecedented wave of super flu.” They said staff were being “pushed to the limit.” The government also pointed to stats showing the NHS is under pressure. A DHSC spokesperson told POLITICO the government had offered the BMA an extended mandate so they could strike in January instead, but the union rejected it. The BMA told POLITICO the extension included “several restrictive conditions.” THE IMPORTANCE OF TRUST The government and NHS bosses have warned the heavy burden on hospitals in December could set the health system up for a very severe winter. NHS statistics published last week show an average of 2,660 patients in hospital with flu per day, a record for this time of year, while the Health Foundation has said the NHS could face “major pressures” if cases continue to climb rapidly in the weeks ahead. Yet, while NHS staff are stretched, Pagel and others argue this year is largely consistent with previous severe flu seasons. However, without being clear about this with the public, some experts are concerned the government’s messaging could do more harm than good. “One of the real issues we have with governments everywhere is trust,” Martin McKee, professor of public health at the London School of Hygiene and Tropical Medicine, told POLITICO. While NHS staff are stretched, experts argue this year is largely consistent with previous severe flu seasons. | Geography Photos/Getty Images “The difficulty is we’ve seen them do all sorts of things for all sorts of motives. That then becomes a problem whenever they are saying something accurate,” McKee said, adding that the government should be more careful in its flu messaging given the declining trust in science. POLITICO put these concerns over trust in science to DHSC, but the department did not respond by the time of publication. A spokesperson for government-sponsored NHS England told POLITICO: “The NHS is not misleading the public — this is the earliest flu season we have seen in recent years with the latest data showing the numbers of patients in hospital with flu is extremely high for this time of year.” The NHS is struggling as it often does in winter, with a spike in delayed discharges — people who are ready to leave hospital but have nowhere to go — posing an extra challenge for hospitals, The Guardian reported Sunday. Hospital admissions for flu per 100,000 rose 23 percent in last week’s data, compared to 69 percent the previous week, but this doesn’t rule out another surge in the weeks ahead. McKee said the NHS was paying the price for chronic underinvestment. “We almost seem surprised that it’s arrived,” he said of the current flu wave, citing a “massive shortage” in beds, IT equipment and scanners.  WHAT THE EXPERTS SAY There is no reason to think the current flu strain (H3N2 sub-clade K) causes more severe disease than other types of flu, Hans Kluge, head of the World Health Organization’s Europe office, told POLITICO. Nor is there any solid evidence that it is more transmissible, said Edoardo Colzani, a flu expert at the European Centre for Disease Prevention and Control. It’s possible the lower level of immunity to this strain could lead to more cases “but this is still speculative at this stage,” Colzani said. “The epidemiological situation at the moment [in the EU] does not seem worse than in previous years apart from the fact that it is two-to-three weeks earlier,” Colzani said. Kluge said it was “about 4 weeks earlier than usual,” which “is not out of the ordinary” and trending similar to the 2022–2023 influenza season. There were some concerns the available flu vaccine might not be a “perfect match” for the current strain, Kluge said, but early data from the U.K. suggests it provides “meaningful protection” and may prevent severe disease and death, especially among vulnerable groups. “We [could] end up having a much bigger wave than usual but we have no evidence,” Pagel said, adding she thought it was “most likely” to peak “in a couple of weeks.” But the available data can’t tell us whether it will be a normal wave that starts and ends early, or an especially bad season, she added.  “We don’t know when it will turn the corner but the actual shape of the wave doesn’t look that different from previous years,” McKee said. The NHS has previously warned of the risk of a “long and drawn-out flu season” due to the early start. According to the WHO, some countries in the southern hemisphere had unusually long flu seasons this year.  “Based on previous trends, this season is expected to peak in late December or early January,” Kluge said. The advice from EU and U.K. authorities remains the same — get a flu vaccine as soon as possible, especially for those in a vulnerable group.

Pediatric respiratory diseases are among the most common and serious health challenges we face worldwide. From examples such as respiratory syncytial virus (RSV) to pertussis (also known as whooping cough), these infections can cause significant illness, hospitalizations, and with some, possible long-term consequences.[1],[2] Worldwide, RSV causes approximately 3.6 million hospitalizations and 100,000 deaths each year in children under five years of age.[3] Yet, many of these infections may be prevented, if we continue to prioritize and strengthen immunization. Immunization is not just a scientific achievement; it’s a public health imperative. And in this new era, Sanofi is at the forefront, driving innovation and access to pediatric immunization, especially when it comes to respiratory disease prevention. Our commitment is global, our ambition bold: to help protect people everywhere against preventable illnesses, with the confidence that every child, every parent, every person, and every healthcare professional deserves. > Immunization is not just a scientific achievement; it’s a public health > imperative. RSV, a leading cause of infant hospitalizations globally, exemplifies both the challenge and the opportunity.[4],[5],[6],[7] With an estimated 12.9 million lower respiratory infections and 2.2 million hospitalizations annually among infants under one year of age,3 the burden is immense. For decades, RSV lacked preventive options for the broad infant population. Some countries in Europe are a good illustration of what is possible when prevention is prioritized. For example, in Galicia, Spain, implementation of a universal program offered to the broad infant population led to notable reductions in RSV-related hospitalization compared with previous seasons.[8] The lesson is clear: when prevention is prioritized like it matters, delivered equitably and integrated into routine care, the impact is quickly seen. This principle applies to other childhood respiratory diseases. Hexavalent combination vaccinations have helped to revolutionize pediatric immunization by combining protection against six diseases into one vaccine. One of these is pertussis, which is especially dangerous for children who haven’t received all their vaccinations yet, and have a four-fold higher risk of contracting whooping cough.[9]  For younger infants pertussis is high risk, with over 40 percent of infants under six months of age requiring hospitalization.[10] These data demonstrate how delayed or missed vaccine doses can leave children vulnerable. By combining vaccines into a single shot, immunization uptake can be improved, increasing acceptance with efficient and equitable delivery and helping reduce disease burden at scale.[11],[12] > Some countries in Europe are a good illustration of what is possible when > prevention is prioritized. For example, in Galicia, Spain, implementation of a > universal program offered to the broad infant population led to notable > reductions in RSV-related hospitalization compared with previous seasons. Good uptake is crucial for protecting children. Where programs are fragmented, under-resourced or underfunded, equity gaps worsen along familiar lines – income, access and information. The recent resurgence of some preventable diseases is not just a warning; it’s a call to action.[13],[14],[15] Sustaining protection against respiratory diseases in children, increasing vaccination coverage rates, and embracing innovation to help protect against more diseases must be a collective priority.[11],[12] We must not let misinformation or complacency erode public trust in immunization. The evidence is clear: prevention works. Today, we have a unique opportunity to showcase that impact and redefine the future of respiratory health in children. > We must not let misinformation or complacency erode public trust in > immunization. The evidence is clear: prevention works. The science is sound. The approach for protecting infants against respiratory infections is clear. Our children deserve nothing less. -------------------------------------------------------------------------------- [1] Glaser EL, et al. Impact of Respiratory Syncytial Virus on Child, Caregiver, and Society. Journal of Infectious Diseases. 2022;226(Supplement_2):S236-S241 [2] Kardos P, et al. Understanding the impact of adult pertussis and its complications. Hum Vaccin Immunother. 2024. [3] Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022;399:2047-2064. [4] Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. The Pediatric infectious disease journal. 2002;21(7):629-32. [5] McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. Journal of Perinatology: official journal of the California Perinatal Association. 2016;36(11):990-6. [6] Rha B, et al. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics. 2020;146:e20193611. [7] Arriola CS, et al. Estimated Burden of Community-Onset Respiratory Syncytial Virus-Associated Hospitalizations Among Children Aged <2 Years in the United States, 2014-15. J Pediatric Infect Dis Soc. 2020;9:587-595. [8] Ares-Gómez S, et al. NIRSE-GAL Study Group. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infectious Diseases. 2024; 24: 817-828. [9] Centers for Disease Control and Prevention. 2019 Final Pertussis Surveillance Report. Accessed 4 March 2025 [10] Glanz, J. M., et al. (2013) Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age. JAMA Pediatr. doi: 10.1001/jamapediatrics.2013.2353 [11] Fatima M, Hong KJ. Innovations, Challenges, and Future Prospects for Combination Vaccines Against Human Infections. Vaccines (Basel). 2025 Mar 21;13(4):335. doi: 10.3390/vaccines13040335. PMID: 40333234; PMCID: PMC12031483. [12] Maman K, Zöllner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: From beliefs to evidence. Hum Vaccin Immunother. 2015;11(9):2132-41. doi: 10.1080/21645515.2015.1044180. PMID: 26075806; PMCID: PMC4635899. [13] Liu J, Lu G, Qiao J. Global resurgence of pertussis in infants BMJ 2025; 391 :r2169 doi:10.1136/bmj.r2169 [14] Jenco M. AAP, CHA call for emergency declaration to address surge of pediatric illnesses. AAP News. 2022 [15] Wang, S., Zhang, S., & Liu, J. (2025). Resurgence of pertussis: Epidemiological trends, contributing factors, challenges, and recommendations for vaccination and surveillance. Human Vaccines & Immunotherapeutics, 21(1). https://doi.org/10.1080/21645515.2025.2513729 MAT-GLB-2506084 

LONDON — Boris Johnson, look away now. The 800-page report from Britain’s official inquiry into the coronavirus pandemic landed Thursday evening. It makes for grim reading for the country’s former prime minister, and much of his top team. Johnson has yet to respond. But the inquiry machine-guns a “too little, too late” government response to the early raging of the virus in 2020, a “toxic culture” in No. 10 Downing Street under the then-PM — and a serious failure to take heed of mistakes made. “Unless the lessons are learned and fundamental change is implemented, the human and financial cost and sacrifice of the Covid-19 pandemic will have been in vain,” the inquiry’s chair Heather Hallett, warned as the report was published Thursday. POLITICO pored over the full report to full out some of the biggest recipients of criticism. 1) BORIS JOHNSON COULDN’T MAKE HIS MIND UP Johnson is roundly criticized for failing to take the virus seriously enough in the initial months, for “oscillating” between different decisions on whether to actually introduce a lockdown, and for a host of controversial comments which caused offense to victims’ families when they came out during the inquiry’s evidence gathering process.  Particular criticism is reserved for Johnson as boss. The culture in Johnson’s No. 10 is described as “toxic and chaotic.” He is accused of “reinforcing” a workplace where the views of others, particularly women, were ignored — and of “encouraging” the behavior of his chief aide, Dominic Cummings. 2) DOMINIC CUMMINGS MADE THE CULTURE WAY WORSE — BUT SAVED LIVES Cummings arguably comes in for even harder criticism than Johnson. The report accuses the then-PM’s chief aide of having “materially contributed to the toxic and sexist workplace culture at the heart of the U.K. government.” It says he was a “destabilising influence” at a time of crisis — and that he was at fault for a “culture of fear, mutual suspicion and distrust” in government. Cummings is, however, praised by the report for his “commendable action” in bringing about a change in the government’s early pandemic strategy, which saved lives.  The culture in Boris Johnson’s No. 10 is described as “toxic and chaotic.” | Wiktor Szymanowicz/Getty Images 3) MATT HANCOCK WASN’T TRUSTED TO BE STRAIGHT WITH PEOPLE The short-lived reality TV star Matt Hancock is a figure of fun in U.K. politics these days — but he once held a role of enormous importance as health secretary during the pandemic.  For his contribution to Britain’s efforts as the virus initially spread, Hancock earns multiple instances of harsh criticism in the report.  Hancock is slammed for the “overenthusiastic impression” he gave to Johnson and top officials on his department’s readiness to face a pandemic, and it is said he gained a reputation for “overpromising and underdelivering.” The report even says concerns were raised about Hancock’s reliability and trustworthiness in meetings as Britain grappled with how to respond in the early days. The report ultimately says Britain should have locked down a week earlier than it did in March 2020, blaming officials, politicians and scientists for not moving quicker. It argues that the failure to do so came at a cost of around 23,000 lives. 4) CHRIS WORMALD SHOULD’VE DONE MORE Government officials were concerned that the Covid inquiry could prove embarrassing for Chris Wormald — who now serves as Prime Minister Keir Starmer’s cabinet secretary, a supremely powerful role at the head of Britain’s civil service. During the pandemic, Wormald was the top civil servant at Hancock’s Department of Health and Social Care, which is repeatedly criticized for giving false impressions on how prepared it was. While Hancock is widely blamed for this, the report does slam Wormald for failing to “rectify” the health secretary’s overconfidence. It says his failure to take any action “gave rise to additional concerns about the effectiveness of Wormald’s leadership.  That was as bad as it got for the current Cabinet Secretary, who might breathe a sigh of relief. Dominic Cummings is praised by the report for his “commendable action” in bringing about a change in the government’s early pandemic strategy, which saved lives. | Wiktor Szymanowicz/Getty Images 5) BITS OF THE BRITISH STATE ITSELF WERE SERIOUSLY SHAKY Whitehall itself comes in for some stark criticism, although the report stops short of a damning indictment of the whole system. The Cabinet Office — often referred to as the wiring at the center of government — is particularly slammed for failing to take more of a lead in early pandemic decision making. The report says that the government’s decision making structures “required improvement” during the pandemic, and that Johnson often sidelined his cabinet in favor of “centralised decision making.”  Brief sections on Welsh and Scottish governing cultures during the pandemic conclude that neither had real issues with relationships, though then-First Minister Nicola Sturgeon is accused of hogging the limelight with her daily lockdown press conferences, even if there’s praise for her “serious and diligent” approach to leading Scotland through the pandemic.

As Europe redefines its life sciences and biotech agenda, one truth stands out: the strength of our innovation lies in its interconnection between human and animal health, science and society, and policy and practice. This spirit of collaboration guided the recent “Innovation for Animal Health: Advancing Europe’s Life Sciences Agenda” policy breakfast in Brussels, where leading voices from EU politics, science and industry came together to discuss how Europe can turn its scientific excellence into a truly competitive and connected life sciences ecosystem. Jeannette Ferran Astorga / Via Zoetis Europe’s role in life sciences will depend on its ability to see innovation holistically. At Zoetis we firmly believe that animal health innovation must be part of that equation, as this strengthens resilience, drives sustainability, and connects directly to the wellbeing of people. Innovation without barriers Some of humanity’s greatest challenges continue to emerge at the intersection of human, animal and environmental health, sometimes with severe economic impact. The recent outbreaks of diseases like avian influenza, African swine fever and bluetongue virus act as reminders of this. By enhancing the health and welfare of animals, the animal health industry and veterinarians are strengthening farmers’ livelihoods, supporting thriving communities and safeguarding global food security. This is also contributing to protecting wildlife and ecosystems. Meanwhile, companion animals are members of approximately half of European households. Here, we have seen how dogs and cats have become part of the family, with owners now investing a lot more to keep their pets healthy and able to live to an old age. Because of the deepening bonds with our pets and their increased longevity, the demand for new treatment alternatives is rising continuously, stimulating new research and innovative solutions making their way into veterinary practices. Zoonotic diseases that can be transferred between animals and humans, like rabies, Lyme disease, Covid-19 and constantly new emerging infectious diseases, make the rapid development of veterinary solutions a necessity. Throughout the world, life sciences are an engine of growth and a foundation of health, resilience and sustainability. Europe’s next chapter in this field will also be written by those who can bridge human and animal health, transforming science into solutions that deliver both economic and societal value. The same breakthroughs that protect our pets and livestock underpin the EU’s ambitions on antimicrobial resistance, food security and sustainable agriculture. Ensuring these innovations can reach the market efficiently is therefore not a niche issue, it is central to Europe’s strategic growth and competitiveness. This was echoed at the policy event by Dr. Wiebke Jansen, Policy Lead at the Federation of Veterinarians of Europe (FVE) when she noted that ‘innovation is not abstract. As soon as a product is available, it changes the lives of animals, their veterinarians and the communities we serve. With the many unmet needs we still face in animal health, having access to new innovation is an extremely relevant question from the veterinary perspective.’ Enabling innovation through smart regulation To realize the promise of Europe’s life sciences and biotech agenda, the EU must ensure that regulation keeps pace with scientific discovery. The European Commission’s Omnibus Simplification Package offers a valuable opportunity to create a more innovation-friendly environment, one where time and resources can be focused on developing solutions for animal and human health, not on navigating overlapping reporting requirements or dealing with an ever increasing regulatory burden. > In animal health, biotechnology is already transforming what’s possible — for > example, monoclonal antibodies that help control certain chronic conditions or > diseases with unprecedented precision. Reviewing legislative frameworks, developing the Union Product Database as a true one-stop hub or introducing digital tools such as electronic product information (e-leaflets) in all member states, for instance, would help scientists and regulators alike to work more efficiently, thereby enhancing the availability of animal health solutions. This is not about loosening standards; it is about creating the right conditions for innovation to thrive responsibly and efficiently. Science that serves society Europe’s leadership in life sciences depends on its ability to turn cutting-edge research into real-world impact, for example through bringing new products to patients faster. In animal health, biotechnology is already transforming what’s possible — for example, monoclonal antibodies that help control certain chronic conditions or diseases with unprecedented precision. Relieving itching caused by atopic dermatitis or alleviating the pain associated with osteoarthritis significantly increases the quality of life of cats and dogs — and their owners. In addition, diagnostics and next-generation vaccines prevent outbreaks before they start or spread further. Maintaining a proportionate, benefit–risk for veterinary medicines allows innovation to progress safely while ensuring accelerated access to new treatments. Supporting science-based decision-making and investing in the European Medicines Agency’s capacity to deliver efficient, predictable processes will help Europe remain a trusted partner in global health innovation. Continuum of Care / Via Zoetis A One Health vision for the next decade Europe is not short of ambition. The EU Biotech Act and the Life Sciences Strategy both aim to turn innovation into a driver of growth and wellbeing. But to truly unlock their potential, they must include animal health in their vision. The experience of the veterinary medicines sector shows that innovation does not stop at species’ borders; advances in immunology, monoclonal antibodies and the use of artificial intelligence benefit both animals and humans. A One Health perspective, where veterinary and human health research reinforce each other, will help Europe to play a positive role in an increasingly competitive global landscape. The next five years will be decisive. By fostering proportionate, science-based adaptive regulation, investing in digital and institutional capacity, and embracing a One Health approach to innovation, Europe can become a genuine world leader in life sciences — for people and the animals that are essential to our lives. -------------------------------------------------------------------------------- Disclaimer POLITICAL ADVERTISEMENT * The sponsor is Zoetis Belgium S.A. * The political advertisement is linked to policy advocacy on the EU End-of-Life Vehicles Regulation (ELVR), circular plastics, chemical recycling, and industrial competitiveness in Europe. More information here.

Today, as the world reaches a critical juncture in the fight against HIV/AIDS, tuberculosis (TB) and malaria, the EU must choose: match scientific breakthroughs with political will and investment or retreat, putting two decades of hard-won progress at risk. Having saved over 70 million lives, the Global Fund to Fight AIDS, Tuberculosis, and Malaria (the Global Fund) has proven what smart, sustained investment can achieve.  But the impact of its work — the lives protected, the life expectancy prolonged, the systems strengthened, the innovations deployed — is now under threat due to declining international funding.  > The real question is no longer whether the EU can afford to invest in the > Global Fund, but whether it can afford to let these hard-won gains unravel. The real question is no longer whether the EU can afford to invest in the Global Fund, but whether it can afford to let these hard-won gains unravel. Declining international funding, climate change, conflict and drug resistance are reversing decades of progress. HIV prevention is hampered by rising criminalization and attacks on key populations, with 1.3 million new infections in 2024 — far above targets. TB remains the deadliest infectious disease, worsened by spreading multidrug resistance, even in Europe. Malaria faces growing resistance to insecticides and drugs, as well as the impacts of extreme weather. Without urgent action and sustained investment, these threats could result in a dangerous resurgence of all three diseases. The stakes could not be higher  The Global Fund’s latest results reveal extraordinary progress. In 2024 alone: * 25.6 million people received lifesaving antiretroviral therapy, yet 630,000 still died of AIDS-related causes; * 7.4 million people were treated for TB, with innovations like AI-powered diagnostics reaching frontline workers in Ukraine; and * malaria deaths, primarily among African children under five, have been halved over two decades, with 2.2 billion mosquito nets distributed and ten countries eliminating malaria since 2020. Yet one child still dies every minute from this treatable disease.  What makes this moment unprecedented is not just the scale of the challenge, but the scale of the opportunity. Thanks to extraordinary scientific breakthroughs, we now have the tools to turn the tide:  * lenacapavir, a long-acting antiretroviral, offers new hope for the possibility of HIV-free generations; * dual active ingredient mosquito nets combine physical protection with intelligent vector control, transforming malaria prevention; and  * AI-driven TB screening and diagnostics are revolutionizing early detection and treatment, even in the most fragile settings. Some of these breakthroughs reflect Europe’s continued research and development and the private sector’s leadership in global health. BASF’s dual-active-ingredient mosquito nets, recently distributed by the millions in Nigeria, are redefining malaria prevention by combining physical protection with intelligent vector control. Delft Imaging’s ultra-portable digital X-ray devices are enabling TB screening in remote and fragile settings, while Siemens Healthineers is helping deploy cutting-edge AI software to support TB triage and diagnosis.  But they must be deployed widely and equitably to reach those who need them most. That is precisely what the Global Fund enables: equitable access to cutting-edge solutions, delivered through community-led systems that reach those most often left behind. A defining moment for EU Leadership The EU has a unique chance to turn this crisis into an opportunity. The upcoming G20 summit and the Global Fund’s replenishment are pivotal moments.  President Ursula von der Leyen and Commissioner Síkela can send a clear, unequivocal signal: Europe will not stop at “almost”. It will lead until the world is free of AIDS, tuberculosis and malaria.  The Global Fund is a unique partnership that combines financial resources with technical expertise, community engagement and inclusive governance. It reaches those often left behind — those criminalized, marginalized or excluded from health systems.  > Even in Ukraine, amid the devastation of war, the Global Fund partnership has > ensured continuity of HIV and TB services — proof that smart investments > deliver impact, even in crisis. Its model of country ownership and transparency aligns with Africa’s agenda for health sovereignty and with the EU’s commitment to equity and human rights. Even in Ukraine, amid the devastation of war, the Global Fund partnership has ensured continuity of HIV and TB services — proof that smart investments deliver impact, even in crisis. The cost of inaction Some may point to constraints in the Multiannual Financial Framework. But history shows that the EU has consistently stepped up, even in difficult fiscal times. The instruments exist. What’s needed now is leadership to use them. Failure to act would unravel decades of progress. Resurgent epidemics would claim lives, destabilize economies and undermine global health security. The cost of inaction far exceeds the price of investment. For the EU, the risks are strategic as well as moral. Stepping back now would erode the EU’s credibility as champion of human rights and global responsibility. It would send the wrong message, at precisely the wrong time.  Ukraine demonstrates what is at stake: with Global Fund support, millions continue to receive HIV and TB services despite war. Cutting funding now would risk lives not only in Africa and Asia, but also in Europe’s own neighborhood. A call to action Ultimately, this isn’t a question of affordability, but one of foresight. Can the EU afford for the Global Fund not to be fully financed? The answer, for us, is a resounding no. We therefore urge the European Commission to announce a bold, multi-year financial commitment to the Global Fund at the G20.  This pledge would reaffirm the EU’s values and inspire other Team Europe partners to follow suit. It would also support ongoing reforms to further enhance the Global Fund’s efficiency, transparency and inclusivity. > Ultimately, this isn’t a question of affordability, but one of foresight. Can > the EU afford for the Global Fund not to be fully financed? The answer, for > us, is a resounding no. This is more than a funding decision. It is a moment to define the kind of world we choose to build: one where preventable diseases no longer claim lives, where health equity is a reality and where solidarity triumphs over short-termism. Now is the time to reaffirm Europe’s leadership. To prove that when it comes to global health, we will never stop until the fight is won.

BRUSSELS — An adviser to U.S. Health Secretary Robert F. Kennedy Jr. lauded Europe’s data on Covid-19 vaccines in front of European Parliament lawmakers on Wednesday. Robert W. Malone, one of RFK Jr.’s newly selected vaccine advisers to the U.S. Centers for Disease Control and Prevention, said the United States can’t gather and analyze data as well as Europe does it, name-checking the Nordics and the U.K. especially for their systems. “One of the consequences is we can’t do, frankly, as good a job as you can do in epidemiology, which may be part of the reason why in some nation states, we’re getting better data on the Covid harms from Europe, the U.K., than we’re getting from the United States,” Malone said. That’s because, among other things, “we don’t have socialized medicine the same way you do, and we have barriers to ensure patient confidentiality,” he told right-wing MEPs gathered in the Parliament to launch the Make Europe Healthy Again (MEHA) movement with the Patriots for Europe group. Under RFK Jr., the U.S. has tried to reign in who can receive Covid-19 shots, which until recently were offered to everyone over 6 months of age at least once a year.   Europe diverged from American Covid-19 shot recommendations during the pandemic, restricting eligibility to those who would be at greatest risk from catching the virus as well as weighing the possible side effects. Younger men and teenagers, for example, appeared more susceptible to a rare heart condition after vaccination. RFK Jr., who has campaigned against the use of certain vaccines, has cited Europe’s approach to Covid-19 vaccination in his attempts to restrict who in the U.S. should receive it. He has also pushed for pregnant women to avoid using paracetamol (Tylenol), linking its use to increasing rates of autism in the U.S., under his Make America Health Again (MAHA) campaign.

One-sixth of confirmed bacterial infections are resistant to antibiotics and rates of drug-resistance are rapidly growing, presenting a growing threat to public health. Over five years — from 2018 to 2023 — antibiotic resistance rose in over 40 percent of the monitored antibiotics with an average annual rise of 5 percent to 15 percent, found the World Health Organization report, published Monday. The Global Antibiotic Resistance Surveillance Report tracked 22 key antibiotics used to treat infections caused by the eight most common bacterial pathogens, including urinary tract infections and gonorrhea. Antimicrobial resistance (AMR) is one of the biggest public health threats of the 21st century and could make it much harder to treat everyday infections, according to the WHO. It’s mainly caused by the overuse and misuse of medicines, allowing pathogens to become resistant, and is fuelled by poor sanitation and lack of clean water. Bacterial AMR killed 1.27 million people in 2019 and contributed to another 4.95 million deaths that year. “Antimicrobial resistance is outpacing advances in modern medicine, threatening the health of families worldwide,” said Tedros Adhanom Ghebreyesus, WHO director general. “As countries strengthen their AMR surveillance systems, we must use antibiotics responsibly, and make sure everyone has access to the right medicines, quality-assured diagnostics, and vaccines,” he added. The median level of antibiotic resistance in Europe was 10.2 percent, the second-lowest rate of any region and below the global average of 17.2 percent.  The greatest threat comes from gram-negative bacteria, which include E. coli and K. pneumoniae, and are among the most severe bacterial infections. More than 40 percent of E. coli and 55 percent of K. pneumoniae globally are resistant to the first-choice treatment, the report found. Other concerns include the bacteria that causes gonorrhea, which has developed resistance to every drug available for first-line treatment. One drug, ciprofloxacin, is no longer suitable due to widespread resistance, while another, azithromycin, has been removed from routine therapy. Resistance to azithromycin is highest in the European region at almost 26 percent. As bacteria become resistant to first-line antibiotics, doctors must increasingly rely on last-resort treatments, which are more expensive and harder to access, especially in low- and middle-income countries. Development of new antibiotics has slowed to a halt due to the lack of a profitable market and incentives for private companies to invest in them. The European Commission has proposed an exclusivity “voucher” to incentivize companies that develop new antibiotics as part of its pharma package. The European Parliament also wants to introduce market entry rewards for new drugs and an EU subscription payment model — proposals that are currently under debate to upgrade EU pharma rules. Other models, such as the Global Antibiotic Research and Development Partnership, seek to develop new antibiotics on a non-profit basis.

Mortality rates for young adults have increased in Eastern Europe over the past decade, despite global death rates falling. Drug-use, suicide and war are among the causes of death that are rising in Eastern Europe, while earthquakes and climate-related disasters have also pushed up death rates in the region. The Global Burden of Disease report — published in The Lancet on Sunday and presented at the World Health Summit in Berlin — analyzed data from more than 200 countries and territories to estimate the leading causes of illness, mortality and early death worldwide from 1990 to 2023. Between 2000 and 2023, there was a notable rise in deaths among younger adults in Eastern Europe caused by HIV, self-harm and personal violence. In Central Europe, deaths from mental disorders and eating disorders have also risen sharply among teens over the decade. This reflects a global trend — a rise in mental health disorders, with worldwide rates of anxiety increasing by 63 percent and of depression by 26 percent. “The rise of depression and anxiety is very concerning,” coauthor Chris Murray, director of the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, told POLITICO. “We hear a lot of debate as to what the root causes are … but we certainly need to pay attention to try to figure out what’s driving the rise. “ The report shows some overall positive trends: Global mortality rates dropped by 67 percent between 1950 and 2023 and global life expectancy in 2023 was more than 20 years higher compared to 1950. But despite the improvements, the study also highlights “an emerging crisis” of higher death rates in teenagers and young adults in certain regions. In North America and Latin America, for example, deaths among young people increased significantly from 2011 to 2023, mainly due to suicide, drug overdose and high consumption of alcohol. In sub-Saharan Africa, they increased due to infectious diseases and unintentional injuries. In Eastern Europe, the largest increases in mortality were among those aged 15-19 year and 20-24 years, with rates increasing by 54 percent and 40 percent, respectively, between 2011 and 2023. The report also tracks leading causes of mortality worldwide. It found that non-communicable diseases (NCDs) now account for nearly two-thirds of the world’s total mortality and morbidity, led by ischemic heart disease, stroke and diabetes. In particular, in lower-middle and upper-middle income countries there is a “very rapid transition towards non-communicable diseases,” said Murray, driven by factors such as an aging population, slow or no progress on tobacco and air pollution, and rising levels of obesity. In Central Europe and North America, these chronic diseases were primarily driven by an increase in drug use disorders, according to the report. Diabetes and kidney disease also largely contributed to the increase in Central Europe, along with several other regions. “Addressing these trends requires targeted public health interventions, improved health-care access, and socioeconomic policies to mitigate the underlying risk factors,” the report authors urge. The researchers estimate that half of all deaths and disability could be prevented by tackling high levels of blood sugar, overweight and obesity, for example.    The report also points out how conflict has “begun to shift from north Africa and the Middle East to central Europe, eastern Europe, and central Asia,” in recent years due to Russia’s war in Ukraine. This has led to a rise in injury-related deaths. Palestine had the highest mortality rate due to conflict and terrorism of any country in the world. While injury-related deaths caused by specific natural disasters, such as the 2023 earthquake in Turkey and the 2022-23 heatwaves in Europe, are also on the rise. “In central and eastern Europe, heatwaves have been occurring more frequently over the past decade,” the authors said.